Acne Vulgaris - Pipeline Review, H2 2013

Date: August 30, 2013
Pages: 121
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A1FF4E1E589EN
Leaflet:

Download PDF Leaflet

Acne Vulgaris - Pipeline Review, H2 2013
Acne Vulgaris - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Acne Vulgaris - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Acne Vulgaris, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acne Vulgaris. Acne Vulgaris - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Acne Vulgaris.
  • A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Acne Vulgaris pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Acne Vulgaris Overview
Therapeutics Development
An Overview of Pipeline Products for Acne Vulgaris
Acne Vulgaris Therapeutics under Development by Companies
Acne Vulgaris Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Acne Vulgaris Therapeutics - Products under Development by Companies
Acne Vulgaris Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acne Vulgaris Therapeutics Development
Boehringer Ingelheim GmbH
Photocure ASA
Valeant Pharmaceuticals International
Medicis Pharmaceutical Corporation
Galderma S.A.
Toyama Chemical Co. Ltd
AntiCancer, Inc.
XOMA Ltd.
Quest PharmaTech Inc.
Phosphagenics Limited
Foamix Ltd.
AndroScience Corporation
Hygeia Therapeutics, Inc.
NanoBio Corporation
Braintree Laboratories, Inc.
Maruho Co.,Ltd.
Lee's Pharmaceutical Holdings Limited
Ensoltek Co., Ltd.
Ausio Pharmaceuticals, LLC
XBiotech USA, Inc.
Advancell
Acne Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
tretinoin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-440 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-430 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-420 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYG-410 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASCJ-9 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methyl aminolevulinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lipo-4MA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gevokizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-03-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BLI-1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ozenoxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD2475/101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-10229570-AAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-10229570-AAA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
M-108101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-017 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RA-18-C-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CD-5789 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVN-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ANs-29 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(adapalene + clindamycin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Urocanic Acid Derivatives - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antimicrobial Peptide For Acne And Skin Cancer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti Acne Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Acne - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DS-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gonadotropin-Releasing Hormone Antagonists - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sharon-4000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
salicylic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acne Vulgaris Therapeutics - Drug Profile Updates
Acne Vulgaris Therapeutics - Discontinued Products
Acne Vulgaris Therapeutics - Dormant Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Jun 25, 2013: Xoma's Development Partner Servier Launches Proof-of-concept Clinical Program for Gevokizumab
Feb 28, 2013: Meda's Acnex Receives Registration Approval In Europe
Feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment
Jan 07, 2013: Xoma Announces Positive Interim Results From Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris
Dec 12, 2012: XBiotech Announces Positive Phase II Clinical Trial Results For MABp1 In Acne Vulgaris
Jan 13, 2012: Photocure Completes Enrollment In Visonac Phase IIb Study For Acne Treatment
Dec 21, 2011: XOMA Initiates Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris
Jul 15, 2011: Photocure Initiates Enrollment Into Phase II Trial Of Visonac For Treatment Of Acne
Apr 27, 2011: Syntopix Provides Update On SYN1113
Apr 19, 2011: MEDA Files Marketing Authorization Application For Acnex In Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Acne Vulgaris, H2 2013
Products under Development for Acne Vulgaris - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Development by Companies, H2 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Development by Companies, H2 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2013
Boehringer Ingelheim GmbH, H2 2013
Photocure ASA, H2 2013
Valeant Pharmaceuticals International, H2 2013
Medicis Pharmaceutical Corporation, H2 2013
Galderma S.A., H2 2013
Toyama Chemical Co. Ltd, H2 2013
AntiCancer, Inc., H2 2013
XOMA Ltd., H2 2013
Quest PharmaTech Inc., H2 2013
Phosphagenics Limited, H2 2013
Foamix Ltd., H2 2013
AndroScience Corporation, H2 2013
Hygeia Therapeutics, Inc., H2 2013
NanoBio Corporation, H2 2013
Braintree Laboratories, Inc., H2 2013
Maruho Co.,Ltd., H2 2013
Lee's Pharmaceutical Holdings Limited, H2 2013
Ensoltek Co., Ltd., H2 2013
Ausio Pharmaceuticals, LLC, H2 2013
XBiotech USA, Inc., H2 2013
Advancell, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Acne Vulgaris Therapeutics - Drug Profile Updates
Acne Vulgaris Therapeutics - Discontinued Products
Acne Vulgaris Therapeutics - Dormant Products

LIST OF FIGURES

Number of Products under Development for Acne Vulgaris, H2 2013
Products under Development for Acne Vulgaris - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Combination Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013

COMPANIES MENTIONED

Boehringer Ingelheim GmbH
Photocure ASA
Valeant Pharmaceuticals International
Medicis Pharmaceutical Corporation
Galderma S.A.
Toyama Chemical Co. Ltd
AntiCancer, Inc.
XOMA Ltd.
Quest PharmaTech Inc.
Phosphagenics Limited
Foamix Ltd.
AndroScience Corporation
Hygeia Therapeutics, Inc.
NanoBio Corporation
Braintree Laboratories, Inc.
Maruho Co.,Ltd.
Lee's Pharmaceutical Holdings Limited
Ensoltek Co., Ltd.
Ausio Pharmaceuticals, LLC
XBiotech USA, Inc.
Advancell
Acne Vulgaris - Pipeline Review, Q1 2011 US$ 500.00 Feb, 2011 · 54 pages
Pemphigus Vulgaris - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 25 pages
Pemphigus Vulgaris - Pipeline Review, Q2 2011 US$ 500.00 Apr, 2011 · 43 pages
Pemphigus Vulgaris – Pipeline Review, H2 2012 US$ 2,000.00 Dec, 2012 · 32 pages
Acne Vulgaris Global Clinical Trials Review, Q4, 2010 US$ 1,000.00 Dec, 2010 · 67 pages

Ask Your Question

Acne Vulgaris - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: